Product news

Share this article:
Canadian health officials have approved Merck's Januvia (sitagliptin phosphate monohydrate), a once-daily, oral medication in a new class of anti-hyperglycemic agents known as DPP-4 (dipeptidyl peptidase-4) inhibitors. Januvia is approved in combination therapy with metformin, a commonly prescribed diabetes medication, to improve blood sugar (glucose) control in adult patients with type 2 diabetes when diet and exercise plus metformin do not provide adequate glycemic control.     
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.